Disposition of Cefotaxime and Its Metabolite, Desacetylcefotaxime, in Rat: Application of a Pharmacokinetic-Protein Binding Model

References

• Balant L., Dayer P., Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clinical Pharmacokinetics 1985; 10: 101–143
   PubMed Web of Science ®Google Scholar
• Bevill R. F., Korit G. D., Rudawsky G., Dittert L. W., Huang C. H., Hayashi M., Bourne D. W. A. Disposition of sulfadimethoxine in swine: inclusion of protein binding factors in a pharmacokinetic model. Journal of Pharmacokinetics and Biopharmaceutics 1982; 10: 539–550
   PubMedGoogle Scholar
• Bourne D. W. A., Wright A. Modification of the digital computer program NONLIN which allows it to run on the PDP‐11 minicomputer. Australian Journal of Pharmaceutical Sciences 1981; 10: 23–24
   Google Scholar
• Bourne D. W. A., Bialer M., Dittert L. W., Hayashi M., Rudawsky G., Koritz G. D., Bevill R. F. Disposition of sulfadimethoxine in cattle: inclusion of protein binding factors in a pharmacokinetic model. Journal of Pharmaceutical Sciences 1981; 70: 1068–1072
   PubMed Web of Science ®Google Scholar
• Chamberlain J., Coombes J. D., Dell D., Fromson J. M., Ings R. J., Macdonald C. M., McEwen J. Metabolism of cefotaxime in animals and man. Journal of Antimicrobial Chemotherapy 1980; 6(Suppl. A)69–78
   PubMedGoogle Scholar
• Coombes J. D. Metabolism of cefotaxime in animals and humans. Reviews of Infectious Diseases 1982; 4: S325–S332, (Suupl.)
   Google Scholar
• Doumas B. T., Watson W. A., Biggs H. G. Albumin standards and the measurements of serum albumin with Bromcresol green. Clinica Chimica Acta 1971; 31: 87–96
   PubMed Web of Science ®Google Scholar
• Drasar F. A., Farrell W., Howard A. J., Hince C., Leung L., Wiliams J. D. Activity of HR‐756 against Haemophilus influenzae, Bacteroides fragilis, and Gram‐negative rods. Journal of Antimicrobial Chemotherapy 1978; 4: 445–450
   PubMed Web of Science ®Google Scholar
• Fick R. B., Alexander M. R., Prince R. A., Kasik J. E. Penetration of cefotaxime into respiratory secretions. Antimicrobial Agents and Chemotherapy 1987; 31: 815–817
   Google Scholar
• Ganziger U., Haslberger A. Pharmacokinetics of cephalosporins in normal and septicemic rabbits. Antimicrobial Agents and Chemotherapy 1985; 28: 473–477
   Google Scholar
• Guerrini V. H., English P. B., Filippich L. J., Schneider J., Bourne D. W. A. Pharmacokinetics of cefotaxime in the dog. Veterinary Record 1986; 119: 81–83
   Google Scholar
• Guerrini V. H., Filippich L. J., English P. B., Bourne D. W. A. Pharmacokinetics of cefotaxime in sheep. American Journal of Veterinary Research 1983; 44: 1488–1491
   Google Scholar
• Hakim L., Bourne D. W. A., Triggs E. J. High performance liquid chromatographic assay of cefotaxime, desacetylcefotaxime, and ceftriaxone in rat plasma. Journal of Chromatography 1988; 424: 111–117
   PubMed Web of Science ®Google Scholar
• Hayton W. L., Stoeckel K. Age‐associated changes in ceftriaxone pharmacokinetics. Clinical Pharmacokinetics 1986; 11: 76–86
   PubMed Web of Science ®Google Scholar
• Hoffken G., Lode H., Koeppe P., Ruhnke M., Borner K. Pharmacokinetics of cefotaxime and desacetylcefotaxime in cirrhosis of the liver. Chemotherapy 1984; 30: 7–17
   Google Scholar
• Hulse M., Feldman S., Bruckner J. V. Effect of blood sampling schedules on protein drug binding in the rat. Journal of Pharmacology and Experimental Therapeutics 1981; 218: 416–420
   PubMed Web of Science ®Google Scholar
• Ings R. M. J., Reeves D. S., White L. O., Bax R. P., Bywater M. J., Holt H. A. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. Journal of Pharmacokinetics and Biopharmaceutics 1985; 13: 121–142
   Google Scholar
• Limbert M., Seibert G., Schrinner E. The cooperation of cefotaxime and desacetylcefotaxime with respect to antibacterial activity and β‐lactamase stability. Infection 1982; 10: 97–100
   PubMed Web of Science ®Google Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Macdonald C. M., Fromson J. M., McDonald A., Dell D., Chamberlain J., Coombes J. D. Disposition of cefotaxime in rat, dog and man. Arzneimittel Forschung 1984a; 34: 1719–1723
   Google Scholar
• Macdonald C. M., McDonald A., Fromson J. M., Coombes J. D. Cefotaxime: sites and pathway of metabolic conversion. Arzneimittel Forschung 1984b; 34: 1729–1735
   Google Scholar
• McElroy D., Ravis W. R., Clark C. H. Pharmacokinetics of cefotaxime in the domestic cat. American Journal of Veterinary Research 1986; 47: 86–88
   Google Scholar
• McNamara P. J., Gibaldi M., Stoeckel K. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration‐dependent protein binding. I: Theoretical considerations. European Journal of Clinical Pharmacology 1983a; 25: 399–405
   Google Scholar
• McNamara P. J., Gibaldi M., Stoeckel K. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration‐dependent protein binding. II: Physiological significance. European Journal of Clinical Pharmacology 1983b; 25: 407–412
   Google Scholar
• Metzler C. M., Elfring G. L., McEwen A. J. A package of computer programs for pharmacokinetic modelling. Biometrics 1974; 30: 562–563
   Web of Science ®Google Scholar
• Mitruka B. M., Rawnsley H. M., Vadehra B. V. Clinical Biochemical and Hematological Reference Values in Normal Experimental Animals. Masson, New York 1977; 124
   Google Scholar
• Peters G., Pulverer G. Comparative in vitro activity of cefotaxime (HR‐756). Chemohemotherapy 1980; 26: 177–183
   Google Scholar
• Peterson L. R., Gerding D. N. Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: clinically useful concept. Reviews of Infectious Diseases 1980; 2: 340–348
   PubMedGoogle Scholar
• Reeves D. S., White L. O., Holt H. A., Bahari D., Bywater M. J., Bax R. P. Human metabolism of cefotaxime. Journal of Antimicrobial Chemotherapy 1980; 6(Suppl. A)93–101
   PubMedGoogle Scholar
• Pang Sandy K., Kwan K. C. A commentary: Methods and assumptions in the kinetic estimation of metabolite formation. Drug Metabolism and Disposition 1983; 11: 79–84
   PubMed Web of Science ®Google Scholar
• Sosna J. P., Murray P. R., Medoff G. Comparison of the in vitro activities of HR‐756 with cephalothin, cefoxitin, and cefamandole. Antimicrobial Agents and Chemotherapy 1978; 14: 876–879
   Google Scholar
• Stevens L. A., Ings R. M. J., Fromson J. M., Coombes J. D. Whole body autoradiographic and quantitative tissue distribution studies with 14C‐cefotaxime in the rat. Arzneimittel Forschung 1984; 34: 1723–1729
   Google Scholar
• Stoeckel K., McNamara P. J., Brandt R., Plozza‐Nottebrock H., Ziegler W. H. Effects of concentration‐dependent plasma protein binding on ceftriaxone kinetics. Clinical Pharmacology and Therapeutics 1981; 29: 650–657
   PubMed Web of Science ®Google Scholar
• Trang J. M., Jacobs R. F., Kearns G. L., Brown A. L., Wells T. G., Underwood F. L., Kluza R. B. Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis. Antimicrobial Agents and Chemotherapy 1985; 28: 791–795
   PubMed Web of Science ®Google Scholar
• Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Bio‐pharmaceutics 1978; 6: 165–175
   PubMedGoogle Scholar
• Yost R. L., Derendorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Therapeutic Drug Monitoring 1986; 8: 189–194
   PubMed Web of Science ®Google Scholar